Opioid Use Disorder: Pharmacotherapy

$27.00 | CE Hours:9.00 | Intermediate


CE Course Description

The United States is experiencing an opioid addiction epidemic.  This CE course describes general principles of opioid use disorder (OUD) pharmacotherapy and discusses medication formulations, indications, and dosing for the three FDA-approved medications used to treat OUD - methadone, naltrexone, and buprenorphine.  Patient management and monitoring in outpatient settings other than opioid treatment programs as well as medical management of patients with OUD in hospital settings is also discussed.

Author: Substance Abuse and Mental Health Services Administration.  Medications for Opioid Use Disorder.  Treatment Improvement Protocol (TIP) Series 63.  HHS Publication No. (SMA) 18-5063.  Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.

Retrieved from:  https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Executive-Summary/SMA18-5063EXSUMM

CE Course Objectives

1.  Differentiate between mu-opioid receptor full agonists, partial agonists, and antagonist.

2.  Give five indications that a patient is suitable for home induction.

3.  Explain why oral naltrexone is not widely used to treat opioid use disorder.

4.  Judge which OUD medication can be used during pregnancy.

5.  Consider three indications that medically supervised withdrawal using buprenorphine or methadone is appropriate for patients.

6.  Weigh three contraindications to receiving XR-NTX.

CE Outline with Main Points

1.  Overview of Pharmacotherapy for Opioid Use Disorder

a.  Introduction to Medications That Address OUD

b.  Principles of OUD Pharmacotherapy

c.  Overview of Medication Indications and Dosing

2.  Methadone

a.  Formulations

b.  Pharmacology

c.  Bioavailability

d.  Dosing Considerations

e.  Contraindications

f.  Initiating Methadone Treatment

g.  Duration of Methadone Treatment

h.  Methadone Dosing Summary

i.  Enhancing Access to OUD Medication in OTPs

3.  Naltrexone

a.  Formulations

b.  Pharmacology

c.  Dosing Considerations

d.  Naltrexone Dosing Summary

4.  Buprenorphine

a.  Formulations

b.  Pharmacology

c.  Bioavailability

d.  Dosing Considerations

e.  Initiating Buprenorphine Treatment

f.  Duration of Buprenorphine Treatment

5.  Medical Management Strategies for Patients Taking OUD Medications in Office-Based Settings

a.  Patient Selection

b.  Patient Management and Treatment Monitoring

c.  Administrative Considerations

d.  Emergency Protocols and Patient Safety Measures

e.  Recommendations for Staff Member Training

6.  Medical Management of Patients Taking OUD Medications in Hospital Settings

a.  Hospital Settings

b.  Hospitalized or ED Patients Taking Medication for OUD

c.  Hospitalized or ED Patients Not Taking Medication for OUD

d.  Medical Management Plan



Course Development: Each course is identified and reviewed by the appropriate Quantum Units Education consultant with professional and licensed expertise in the various disciplines we serve. Our professional consultants oversee course development to satisfy the needs of various professionals based on their board requirements, rate course degree of difficulty and ensure the course content and exam questions are appropriate, relevant and comprehensive. See our professional staff and their bios here.

*Board Approvals for this course can be found here.
*Questions regarding how to take a course, refunds, grievance policy and ADA policy can be found here.
*Questions regarding this course or need support? Contact us at: support@quantumunitsed.com.

Added On: 2018-09-17

Powered by LIFTOFF Digital | Web Design and Development